Hepatitis D Clinical Trials

7 recruiting

Hepatitis D Trials at a Glance

16 actively recruiting trials for hepatitis d are listed on ClinicalTrialsFinder across 6 cities in 28 countries. The largest study group is Phase 2 with 3 trials, with the heaviest enrollment activity in Milan, Toulouse, and Bucharest. Lead sponsors running hepatitis d studies include Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Mirum Pharmaceuticals, Inc., and Erasmus Medical Center.

Browse hepatitis d trials by phase

Treatments under study

About Hepatitis D Clinical Trials

Looking for clinical trials for Hepatitis D? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Hepatitis D trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Hepatitis D clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting

Evaluation of Patients With Liver Disease

Hepatitis BHepatitis CLiver Disease+1 more
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)8,050 enrolled1 locationNCT00001971
Recruiting
Phase 1Phase 2

Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus

Chronic Hepatitis Delta
Gilead Sciences107 enrolled15 locationsNCT07096193
Recruiting
Phase 2Phase 3

Study to Evaluate Switching to Brelovitug for the Treatment of CHD in Participants Receiving Bulevirtide

Chronic Hepatitis D
Mirum Pharmaceuticals, Inc.120 enrolled22 locationsNCT07454837
Recruiting
Phase 3

A Trial Evaluating Brelovitug (BJT-778) vs Bulevirtide for the Treatment of Chronic Hepatitis Delta Infection (AZURE-2)

Chronic Hepatitis D Infection
Mirum Pharmaceuticals, Inc.172 enrolled44 locationsNCT07200908
Recruiting
Phase 3

A Trial Evaluating Brelovitug vs Delayed Treatment for the Treatment of Chronic Hepatitis Delta Infection (AZURE-4)

Chronic Hepatitis D Infection
Mirum Pharmaceuticals, Inc.80 enrolled27 locationsNCT07298330
Recruiting

Immunological and Virological Characterization of Patients With Chronic HBV-HDV Infection: Outcomes and Response to Bulevirtide Treatment

Hepatitis D
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico192 enrolled1 locationNCT06504485
Recruiting

DELTA DESCRIBE: the French Collaborative Project

Hepatitis D
University Hospital, Limoges734 enrolled1 locationNCT05936073
Recruiting

HDV Screening Study

Hepatitis D Virus Infection
Grace Lai Hung Wong300 enrolled1 locationNCT06889805
Recruiting

National Cohort of Patients Co-infected With Hepatitis B and Delta Viruses

Hepatitis B, ChronicHepatitis D, Chronic
ANRS, Emerging Infectious Diseases800 enrolled38 locationsNCT04166266
Recruiting

Effectiveness and Safety of Bulevirtide (BLV) Therapy in Patients With Chronic Hepatitis Delta (CHD) in Italy (D-SHIELD)

Hepatitis D
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico100 enrolled1 locationNCT06122285
Recruiting

Find HDV and Determine Its Status in Turkey

Hepatocellular CarcinomaCirrhosis, LiverFibrosis, Liver+2 more
Yaşar Bayındır, MD20,000 enrolled2 locationsNCT06248580
Recruiting

Effectiveness and Clinical Outcomes of Long-term Bulevirtide Monotherapy in Patients With HDV-related Compensated Cirrhosis

Hepatitis D
Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico266 enrolled1 locationNCT06397859
Recruiting

HDV-Europe: Prevalence and Outcome of HDV in HIV/HBV Coinfection

Hepatitis D
University Hospital, Bonn8,000 enrolled1 locationNCT06264583
Recruiting

Standardising Care for Hepatitis Delta in the Netherlands

Hepatitis D
Erasmus Medical Center80 enrolled1 locationNCT05903742
Recruiting

Study to Evaluate Efficacy, Safety and Biomarkers of Bulevirtide Treatment in Chronic Hepatitis D Patients

Chronic Hepatitis D
Karolinska University Hospital400 enrolled1 locationNCT06051045
Recruiting
Phase 2

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Subjects with Chronic HBV Infection (CHB) and Chronic HDV Infection (CHD).

Chronic Hepatitis D Virus (HDV) InfectionChronic Hepatitis B Virus (HBV) Infection
Bluejay Therapeutics Inc.72 enrolled9 locationsACTRN12623000105640